{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]}],"title":"Overall"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"title":"On/after Week 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \\<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions. If a participant did not have any RBC transfusions, they were assigned a value of 0.","groups":[{"description":"Participants received placebo IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 2: Placebo"},{"description":"Participants received trilaciclib 240 mg/m\\^2 IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG001","title":"Part 2: Trilaciclib 240 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS included all randomized patients who received at least 1 dose of study drug (etoposide, carboplatin, or trilaciclib). Analyses using the FAS were conducted on the basis of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)","title":"Occurrence of RBC Transfusion in Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}